Last reviewed · How we verify
Monocain (butethamine)
Monocain (generic name: butethamine) is a drug. It is currently in unknown development.
Monocain works by blocking sodium channels in the brain, which can help regulate abnormal electrical activity.
Monocain (butethamine) is a small molecule modality targeting sodium channel alpha subunits in the brain, specifically types I, II, and III. Its exact drug class is unknown, and its commercial status is unclear. Monocain is not FDA-approved for any indications, and its pharmacokinetic properties, such as half-life and bioavailability, are also unknown. As a result, there is limited information available on its safety profile and potential side effects. Further research is needed to fully understand Monocain's mechanism of action and potential therapeutic applications.
At a glance
| Generic name | butethamine |
|---|---|
| Target | Sodium channel alpha subunits; brain (Types I, II, III) |
| Therapeutic area | Neuroscience |
| Phase | unknown |
Mechanism of action
Imagine your brain is like a city with many busy streets. Sodium channels are like traffic lights that help control the flow of electrical signals. When these channels get stuck in the 'on' position, it can lead to problems like seizures or pain. Monocain is like a traffic cop that helps turn off these channels when they're not needed, restoring balance to the brain's electrical activity.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Monocain CI brief — competitive landscape report
- Monocain updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Monocain
What is Monocain?
How does Monocain work?
What is the generic name of Monocain?
What development phase is Monocain in?
What does Monocain target?
Related
- Target: All drugs targeting Sodium channel alpha subunits; brain (Types I, II, III)
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing